Your browser doesn't support javascript.
loading
Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?
Mutlu, Hasan; Salim, Derya Kivrak; Gündüz, Seyda; Eryilmaz, Melek Karakurt; Musri, Fatma Yalçin; Coskun, Hasan Senol.
Afiliación
  • Mutlu H; Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
  • Salim DK; Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
  • Gündüz S; Department of Antalya Research and Training Hospital, Antalya, Turkey.
  • Eryilmaz MK; Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
  • Musri FY; Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
  • Coskun HS; Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
J Cancer Res Ther ; 13(3): 510-513, 2017.
Article en En | MEDLINE | ID: mdl-28862218

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Cisplatino / Taxoides / Fluorouracilo / Neoplasias de Cabeza y Cuello / Recurrencia Local de Neoplasia Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2017 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Cisplatino / Taxoides / Fluorouracilo / Neoplasias de Cabeza y Cuello / Recurrencia Local de Neoplasia Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2017 Tipo del documento: Article